Thought Leadership
Search results
Blog | October 20, 2016
Biogen Dodges IPR Bullet on Key Tysabri® Patents
Fish & Richardson
Read more
Blog | October 13, 2016
Federal Circuit Affirms the Dismissal of a Complaint That Insufficiently Pleaded Joint Infringement
Fish & Richardson
Read more
Blog | October 07, 2016
Amgen Appeals Loss of Neulasta® and Neupogen® Litigation
Fish & Richardson
Read more
Blog | October 06, 2016
EDTX denies exclusion of settlement license and "real estate" apportionment
Fish & Richardson
Read more
Blog | September 30, 2016
Court Orders Entry of Final Judgment of Invalidity in Ongoing Janssen v. Celltrion BPCIA Dispute
Fish & Richardson
Read more
Blog | September 16, 2016
My Intellectual Property Licensor is Bankrupt — Now What?
Fish & Richardson
Read more
Blog | September 06, 2016
D.Ariz excludes expert for not apportioning the rate, but OKs entire product as base
Fish & Richardson
Read more
Blog | August 25, 2016
DDE excludes settlement agreements; allows licenses as a "check"; addresses apportionment of accused products & services
Fish & Richardson
Read more
Blog | August 19, 2016
SDFL allows opinion based in part on plaintiff's licensing proposals (or offers)
Fish & Richardson
Read more
Blog | August 17, 2016
EDTX questions viability of "inexorable flow" doctrine of lost profits
Fish & Richardson
Read more
Blog | August 16, 2016
Federal Circuit Once Again Finds That a Functional Claim Term is Indefinite Even Without the Use of "Means."
Fish & Richardson
Read more
Blog | August 15, 2016
NDCA excludes expert testimony for failure to apportion (including addressing claim scope argument)
Fish & Richardson
Read more